Zhejiang Haisen Pharmaceutical Co., Ltd. Class A

As of June 30, 2026, Zhejiang Haisen Pharmaceutical Co., Ltd. Class A carries a market capitalization of 2.81B, placing it among publicly traded companies globally. Its enterprise value stands at 1.73B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Zhejiang Haisen Pharmaceutical Co., Ltd. Class A has 152.35M shares outstanding.

As of June 30, 2026, Zhejiang Haisen Pharmaceutical Co., Ltd. Class A trades at a trailing price-to-earnings ratio of 19.48. The price-to-sales ratio is 5.08, and the price-to-book ratio stands at 1.81.

As of June 30, 2026, Zhejiang Haisen Pharmaceutical Co., Ltd. Class A trades at an EV/EBITDA multiple of 10.53 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 3.15 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 10.53 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 1.73B versus a market cap of 2.81B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Zhejiang Haisen Pharmaceutical Co., Ltd. Class A maintains a current ratio of 13.39, meaning it holds 13.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.48, indicating conservative leverage, while an interest coverage ratio of 500.68 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Zhejiang Haisen Pharmaceutical Co., Ltd. Class A posted a return on equity (ROE) of 9.77, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 9.66 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 9.03, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 9.73, useful for judging operating efficiency across full business cycles. The company generates approximately 788,898.42 in revenue per employee across its workforce of 694.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.66 indicates how many times Zhejiang Haisen Pharmaceutical Co., Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Zhejiang Haisen Pharmaceutical Co., Ltd. Class A recorded 20.64M in income tax expense. That works out to an effective tax rate of 12.62, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 163.63M, leaving 142.99M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, Zhejiang Haisen Pharmaceutical Co., Ltd. Class A's stock has declined approximately 18.79% over the past 52 weeks. The 50-day moving average sits at 20.38, while the 200-day moving average is 21.76.

Over the twelve months ended June 30, 2026, Zhejiang Haisen Pharmaceutical Co., Ltd. Class A generated 547.89M in revenue and converted that into 142.99M in net income, yielding earnings per share of 0.72. EBITDA reached 163.95M, while operating income came in at 158.24M.

As of June 30, 2026, Zhejiang Haisen Pharmaceutical Co., Ltd. Class A holds 1.09B in cash and equivalents against 7.49M in total debt, resulting in a net debt position of -468.15M. Total book value stands at 1.55B, with working capital of 1.20B providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Zhejiang Haisen Pharmaceutical Co., Ltd. Class A posted a gross margin of 45.88, reflecting its pricing power and cost economics. The operating margin of 28.88 and net profit margin of 26.10 provide insight into operational efficiency.

Zhejiang Haisen Pharmaceutical Co., Ltd. Class A's most recent stock split took place on May 20, 2025 with a 25:37 split ratio.

As of June 30, 2026, Zhejiang Haisen Pharmaceutical Co., Ltd. Class A has an Altman Z-Score of 16.83, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.